Create Vocaloid songs anytime, anywhere.

HAMAMATSU, Japan, Oct. 20, 2025 /PRNewswire/ — Yamaha Corporation will launch a subscription version of the “Mobile VOCALOID Editor an app for iPhone and iPad that allows users to create VOCALOID songs, on October 20 (Mon.) via the App Store. With this new subscription service, users can now enjoy an even easier way to experience VOCALOID music creation.

Yamaha Software “Mobile VOCALOID Editor” (Subscription Version) URL: https://www.vocaloid.com/en/mveditor/

Developed by Yamaha in 2003, VOCALOID singing voice synthesis technology and software creates vocals for songs using lyrics and a melody (musical notation) as input. Released in 2015, “Mobile VOCALOID Editor” is an app for iPhone/iPad that allows users to create songs by simply tapping notes and lyrics on the screen, and has been widely used by many users for its intuitive workflow and wide range of available voicebanks.

With the introduction of the subscription model, the app now features the VOCALOID:AI synthesis engine, the same engine used in the PC/Mac versions of VOCALOID6 which uses artificial intelligence to synthesize more natural, richly expressive singing voices. The new voicebank “asa,” which features a delicate and translucent singing voice, is included as a standard feature, and in addition to the existing voicebanks of characters such as Hatsune Miku, IA, and v flower, the voicebank options have been expanded to include VOCALOID:AI compatible voicebanks such as AI Megpoid and Otomachi Una.

To encourage users to start creating VOCALOID songs more freely and easily with “Mobile VOCALOID Editor,” we have prepared short phrases, such as those that can be freely used for arrangement songs, on the official website.

• Official website: https://www.vocaloid.com/en/mveditor/ 

[Retail Prices and Release Dates]

*Please refer to the official shop for the price of each product: https://www.vocaloid.com/en/mveditor/

[Features of Mobile VOCALOID Editor]

• Authentic VOCALOID Singing, Anytime, Anywhere

“Mobile VOCALOID Editor” allows users to enjoy authentic vocal production anytime and anywhere by entering lyrics in English for each note of the melody in the piano roll on their smartphone or tablet screen. External MIDI devices compatible with iOS can also be connected for input, allowing for more flexible music production in combination with external devices and apps.

• Equipped with the new voicebank “asa“

The subscription version of “Mobile VOCALOID Editor” includes the new voicebank “asa.” This voicebank features a “delicate and translucent singing voice” and allows users to enjoy the natural and expressive singing voice unique to VOCALOID:AI.

• Enables in-app purchases of additional voicebanks

When you want to increase the variety of singing voices or create songs with voicebanks that you like, you can download and purchase over 40 additional character voicebanks such as Hatsune Miku, Megpoid, Otomachi Una, and IA from the in-app store screen. Additional voicebanks are planned to be released sequentially, and by switching to a voicebank of your choice, you can further expand the range of your music production.

• Launch Campaign

To celebrate the launch of the subscription version of “Mobile VOCALOID Editor,” we are holding a “Voicebank of Your Choice Giveaway Campaign” for users who post their created songs on social media between today and November 9 (Sun.). Please check the official “Mobile VOCALOID Editor” website for campaign details.

[Product Summary]

* VOCALOID and VOCALO are trademarks or registered trademarks of Yamaha Corporation.

* Other product names, company names, etc. in this document are trademarks or registered trademarks of this company and other companies.

About Yamaha Corporation

Founded in 1887, the Yamaha Group has established itself as a global leader in manufacturing musical instruments and audio products while continuing to engage in various business activities to grow services related to sound and music. Yamaha operates over 60 subsidiaries worldwide, dedicated to serving millions of customers across six continents, focusing on delivering excellence in quality and innovation, prioritizing our sustainability efforts and contributing to people’s “well-being.” To learn more, visit https://www.yamaha.com/en/.

BERLIN, Oct. 20, 2025 /PRNewswire/ — At the 2025 European Society for Medical Oncology (ESMO) Congress, a Phase III clinical study on disitamab vedotin plus toripalimab versus chemotherapy as first-line treatment for HER2-expressing locally advanced or metastatic urothelial carcinoma (RC48-C016) sponsored by RemeGen Co., Ltd. was presented at the Presidential Symposium by Professor Jun Guo from Beijing Cancer Hospital. It’s the first time a research led by Chinese scholars in the field of urological oncology has ever been selected in this honorable session. The full manuscript was simultaneously published online in The New England Journal of Medicine (NEJM). This marks the first time that the results of a Chinese evidence-based medical research in the field of urothelial carcinoma have been recognized by both an authoritative international academic conference and a top-tier journal.

The results showed that the RC48-C016 study met the dual primary endpoints of Progression-Free Survival (PFS) and Overall Survival (OS). The Blinded Independent Central Review (BICR)-assessed median PFS reached 13.1 months, and the median OS reached 31.5 months, demonstrating both statistical and clinical significance.

The RC48-C016 trial is by now the only randomized controlled study from China providing high-level evidence for HER2-ADC as a first-line treatment of HER2-expressing (IHC 1+/2+/3+) locally advanced/metastatic urothelial carcinoma (la/mUC). The results garnered high attention and sparked lively discussion among global scholars upon release.

Comprehensive Superiority: Meeting Both PFS and OS Primary Endpoints

On the afternoon of October 19 (local time), a pivotal moment arrived at the ESMO Congress: Professor Guo Jun, the principal investigator of the RC48-C016 study, delivered a featured oral presentation at the Presidential Symposium, unveiling the breakthrough results globally for the first time.

The RC48-C016 study is a randomized controlled, multi-center, phase III clinical trial. It compares the efficacy and safety of disitamab vedotin combined with toripalimab versus gemcitabine combined with cisplatin or carboplatin in patients with locally advanced or metastatic urothelial carcinoma (la/mUC) who have not received systemic treatment and have HER2 expression (HER2 IHC 1+/2+/3+). The study was initiated in June 2022, with 76 clinical research centers across the country participating, and a total of 484 patients were enrolled. The dual primary endpoints of the study are PFS and OS, and the secondary endpoints include objective response rate (ORR), disease control rate (DCR), and safety, etc.

Results as of March 31, 2025, showed:

• Regarding PFS, the median PFS in the disitamab vedotin combination group reached 13.1 months, more than doubling the 6.5 months in the chemotherapy group and reducing the risk of disease progression or death by 64% (Hazard Ratio [HR] =0.36, 95% CI: 0.28 – 0.46, P < 0.0001).
• The OS data were equally exciting. In this interim survival analysis, the median OS in the disitamab vedotin combination group was 31.5 months, compared to 16.9 months in the platinum-based chemotherapy group. The delayed disease progression has been well translated into long-term survival benefit as the overall survival time almost doubled as compared to chemotherapy, with a 46% reduction in the risk of death (HR = 0.54, 95% CI: 0.41 – 0.73, P < 0.0001).
• Regarding tumor response, the ORR assessed by BICR reached 76.1% in the disitamab vedotin combination group, far exceeding the 50.2% in the chemotherapy group. For disease control, the DCR in the disitamab vedotin combination group reached 91.4%, significantly higher than the 77.6% in the chemotherapy group.
• In key subgroup analyses, significant improvements in median PFS and median OS were observed in the disitamab vedotin combination group compared to the platinum-based chemotherapy across subgroups, regardless of cisplatin eligibility, HER2 expression status, or primary tumor site.
• Furthermore, the combination regimen demonstrated a better safety profile. The overall incidence of Grade ≥3 treatment-related adverse events was only 55.1% in the disitamab vedotin combination group, significantly lower than the 86.9% in the chemotherapy group.

“This is the world’s first large-scale Phase III randomized controlled clinical study in the first-line treatment of HER2-expressing Chinese mUC patients, which demonstrated that HER2-ADC combined with immunotherapy was superior to standard platinum-based chemotherapy, potentially establishing the combination therapy of disitamab vedotin and immunotherapy as the standard of care in the first-line treatment of advanced HER2-expressing mUC. This not only signifies that China’s innovative drug development is leading transformations in cancer treatment globally but also provides critical rationale for exploring similar combination strategies in treating other cancers.” As Professor Guo Jun commented, the result of the RC48-C016 study confirmed that the efficacy of disitamab vedotin + toripalimab combination regimen surpassed that of traditional chemotherapy as first-line treatment for advanced mUC, potentially marking a major shift in the treatment landscape for urothelial carcinoma. It promotes innovation in Chinese diagnostic and treatment pathways while providing valuable evidence for global clinical practice.

During the subsequent expert commentary session, Professor Andrea Necchi from Italy’s IRCCS San Raffaele Hospital spoke highly of RC48-C016 study. He pointed out that the study represents a significant breakthrough in the treatment of HER2-positive urothelial carcinoma. Compared to chemotherapy, the combination therapy of disitamab vedotin and toripalimab significantly improves patients’ PFS and OS, demonstrating substantial statistical significance and clinical value, thereby offering a novel treatment option for this patient population.

Precision Treatment, Benefiting the Full Spectrum of HER2-Expressing Population (IHC 1+/2+/3+)

Urothelial carcinoma is the most common malignant tumor of the urinary system, representing a significant area of clinical unmet need.

Chinese researchers have been at the forefront of exploring HER2-ADC therapy for UC. The HER2-ADC disitamab vedotin was first approved in China in 2021 for the treatment of HER2-overexpressing (IHC 2+/3+) advanced or metastatic urothelial carcinoma, demonstrating excellent efficacy and consistent safety with that observed in prior clinical trials.

RC48-C016 study prospectively extended its clinical design to the full HER2-expressing population (IHC 1+/2+/3+). Among 765 patients tested for HER2, 632 patients had HER2-expressing characteristics (IHC 1+/2+/3+), accounting for approximately 82.6% of the tested population. The study enrolled 484 patients, who were randomized in a 1:1 ratio to groups. Stratification factors were pre-specified in the study design, primarily including cisplatin eligibility, HER2 expression status (IHC 1+ vs. IHC 2+/3+), and presence of visceral metastasis.

The results showed that the efficacy observed in the disitamab vedotin plus toripalimab regimen were consistent across all pre-specified subgroups. Regardless of HER2 expression status, cisplatin eligibility, or whether the tumor originated in the upper or lower urinary tract, disitamab vedotin combined with toripalimab significantly improved PFS and OS compared to chemotherapy, robustly demonstrating its benefit for the full demonstrating its benefit for the full HER2-expressing population (IHC 1+/2+/3+) with urothelial carcinoma.

“The significant survival benefit achieved by disitamab vedotin combined with toripalimab is not subject to the level of HER2 expression or cisplatin eligibility status, delivering benefit to populations with different characteristics,” Professor Guo Jun stated, noting that its benefit for the full HER2-expressing population (IHC 1+/2+/3+) is one of the most groundbreaking findings of this study.

Disitamab Vedotin Combined with Immunotherapy, Establishing a New Benchmark in UC First-Line Treatment

Undoubtedly, RC48-C016 study is a milestone in the global first-line treatment landscape for advanced urothelial carcinoma, signifying a fundamental shift in the treatment paradigm for HER2-expressing patients:

Firstly, RC48-C016 study is the world’s first Phase III head-to-head trial to demonstrate that the combination of HER2-ADC and immunotherapy is significantly superior to traditional platinum-based chemotherapy in the first-line treatment of HER2-expressing (IHC 1+/2+/3+) advanced urothelial carcinoma. The release of its outstanding data on PFS, OS, ORR, and safety provides strong decision-making basis for clinicians, which will promote this combination to become a new first-line treatment standard for Chinese mUC patients and is expected to rewrite clinical guidelines.

Secondly, the study successfully implements the concept of precision medicine in urothelial carcinoma based on significant biomarker characteristics. By extending the beneficiary population from the traditional HER2-high (IHC 2+/3+) to the full HER2-expressing (IHC 1+/2+/3+) population, it enables over 80% of urothelial carcinoma patients to potentially benefit significantly from this treatment regimen. In the current clinical practice in China where HER2 routine detection in urothelial carcinoma has been achieved, the study provides a preferred precise treatment plan for the majority of patients and precise basis for anti-HER2 treatment, promoting a comprehensive upgrade in the global treatment concept and strategy for urothelial carcinoma and leading the continuous exploration of this combination therapy in different disease stages of urothelial carcinoma.

Thirdly, this combination regimen substantially reduces the toxicity associated with traditional platinum-based chemotherapy, significantly improving patient treatment tolerance and compliance, and providing a foundation for subsequent continuous therapy, achieving an optimized balance between tumor control, long-term survival, and quality of life.

Since its marketing four years ago, disitamab vedotin, relying on its outstanding efficacy, has achieved a progress from late-line to first-line treatment in the field of urothelial carcinoma, comprehensively breaking through the bottlenecks of traditional chemotherapy and continuously expanding the boundaries of its clinical value. The revelation of RC48-C016 study data once again demonstrates its huge clinical treatment potential.

Based on the breakthrough results of the RC48-C016 study, RemeGen Co., Ltd. submitted a New Drug Application (NDA) in China in July of this year for the new indication of disitamab vedotin combined with toripalimab for the first-line treatment of HER2-expressing locally advanced or metastatic urothelial carcinoma. This will not only address domestic clinical needs but also holds the potential to become a “Chinese Solution” influencing the global treatment landscape.

It is believed that with extended follow-up, disitamab vedotin will continue to yield clinical benefit data for broader treatment prospects.

WUHU, China, Oct. 20, 2025 /PRNewswire/ — The Co-Creation Workshop: October 19, EXEED held its New Product Co-Creation Workshop under the theme “Shift to Tomorrow” at REBOX. The spot was the New Venue of the Old Shipyard 1900. The Workshop brought the global debut of its new family design language and the industry-leading Texxeract new energy technology.

Texxeract Technology Launch: The newly launched Texxeract Energy Cube Technology supports PHEV, REEV, and BEV powertrains. It delivers outstanding performance in efficiency, safety, and performance, with multiple indicators reaching industry-leading or exclusive levels.

New Family Design Language and Vehicle Debut: EXEED unveiled its new family design philosophy “Perpetua” (meaning “eternal” and “continuous”). The three new models — ES GT, RX, and ES Sport — embody this philosophy through pure, fluid forms and sculpted light-and-shadow surfaces, expressing a unique sense of aesthetic elegance.

October 19, EXEED successfully hosted the Shift to Tomorrow New Product Co-Creation Workshop at REBOX, Old Shipyard 1900. As a strategic brand event, it showcased EXEED’s green innovation achievements in an Eco-Exhibition, including the global premiere of Texxeract Energy Cube Technology covering PHEV, REEV, and BEV platforms. And also the debut of EXEED’s new family design language, as well as the presentation of AiMOGA. Together, these highlights demonstrated EXEED’s solid strength in technological R&D, design innovation, and intelligent interaction.

Texxeract Technology World Premiere

As EXEED’s exclusive new technology system, the newly launched Texxeract Energy Cube Technology focuses on advancing the brand’s electrification. This will build an exceptional global NEV ecosystem for users worldwide. This technology redefines industry benchmarks across three core dimensions — efficiency, safety, and performance. Several key indicators for this technology rank among the industry leaders or are unique to it.

As for efficiency, Texxeract achieves breakthroughs in ultra-long range, ultra-fast charging, and ultra-low energy consumption. Pure EV models can complete a 20%–80% fast charge in just 10 minutes. Equipped with the IEC Intelligent Energy Management System, it maximizes energy utilization. For example, the ET REEV achieves the industry’s highest fuel-to-electric conversion rate. It generates 3.7 kWh of electricity with 1 liter of fuel. And it could deliver a combined range of 1,180 km on a full charge and full tank. This is putting EXEED at the forefront of global energy efficiency management.

As for safety, Texxeract’s safety technologies have been fully validated in existing models. The technology offers cutting-edge physical protection for the battery. Thus, reliable operation is ensured even under extreme conditions. It also enables the system to provide real-time connectivity-based monitoring for comprehensive safety. Models equipped with Texxeract — such as the EXEED ES and RX PHEV — have both achieved E-NCAP five-star safety ratings. Notably, EXEED ES became the first global model to pass China’s six-dimensional electric safety certification, setting a new benchmark for NEV safety standards.

Performance remains Texxeract’s core highlight. Equipped with the iVC Intelligent Vehicle Control System, vehicles deliver strong power, exceptional acceleration, and top-speed performance. The EXEED ES, for example, accelerates 0–100 km/h in just 3.7 seconds. It is also equipped with iATS, making EXEED the only premium NEV brand to feature such a system. This breaks through the traditional limits of new energy vehicles on complex road conditions.

As a next-generation intelligent electrification technology, Texxeract achieves extreme energy efficiency and delivers unparalleled dynamic performance. EXEED demonstrates its strong technological prowess in R&D with several core figures: its globally unique “Four-Power-Unit” Full-Time AWD System (the world’s exclusive quad-motor AWD configuration) offering a maximum combined output of 470 kW, alongside an industry-leading 45.8% hybrid engine efficiency and 98.5% transmission efficiency with its DHT high-efficiency hybrid transmission system. The RX PHEV, powered by Texxeract, accelerates from 0 to100 km/h in 4.62 seconds and has a total range exceeding 1,300 km. In addition, the Workshop introduced the upcoming Texxeract 2.0 technology, which will be implemented on ES7, ET8, and ET9 models by the end of 2027.

Three New Models Embody the Family Design Language

EXEED’s Perpetua design philosophy (meaning eternal and unending) draws inspiration from the myth of Atlantis and the dynamics of ocean waves. Through pure, dynamic, and fluid body proportions, sculpted surfaces of light and shadow, and seamless form transitions, the design expresses a sense of timeless beauty and motion. At this Workshop, three new models that embody this philosophy made their debut: EXEED ES GT in Abyssal Jewel, featuring a floating bumper and aerodynamic C-pillar, exuding dynamic elegance. EXEED RX, presented in Starlight Ocean, features a digital grille and Starry Sky DRL, creating a commanding presence. The EXEED ES Sport Sedan enhances its sporty character with a revised bumper, air-guiding side skirts, and a large rear diffuser. All three models inherit the Stellar Concept design DNA, showcasing the distinctive charm of EXEED’s new family design language.

Conclusion:

The success of this Co-creation Workshop, together with the Eco-exhibition and the AiMOGA showcase, formed the core highlights of the EXEED International User Summit. These events offered a clear view of the brand’s development roadmap and technological strength, and also deepened the ties with partners. Looking ahead, EXEED will take the Texxeract technology as its core technology and the new family design language as its aesthetic benchmark. EXEED will accelerate the global rollout of cutting-edge products such as the ES and ET series. These models will successively enter highly regulated markets, including Norway, Denmark, and Germany. They will mark substantial breakthroughs in the premium NEV segment and create greater value for global users.

SEOUL, South Korea, Oct. 20, 2025 /PRNewswire/ — HD Hyundai announced that Executive Vice Chairman Chung Kisun has been promoted to Chairman in its latest executive appointments.

Chairman Chung holds a bachelor’s degree in Economics from Yonsei University and an MBA from Stanford University in the United States. He began his career in 2009 in the Finance Team of the Corporate Planning Division at HD Hyundai Heavy Industries. Since then, he has served as Head of Management Support at HD Hyundai, Head of Ship Sales at HD Hyundai Heavy Industries, and CEO of HD Hyundai Marine Solution. He currently serves as CEO of HD Hyundai, the holding company, as well as HD Korea Shipbuilding & Offshore Engineering, the intermediate holding company for the shipbuilding division. In this latest personnel announcement, Chairman Chung was also appointed Co-CEO of HD Hyundai XiteSolution, where he will lead efforts to overcome the recent downturn in the construction equipment business and establish new growth drivers.

Chairman Chung spearheaded the establishment of HD Hyundai Marine Solution in 2016, developing it into one of the group’s core businesses with a market capitalization of KRW 11 trillion. In 2021, he led the acquisition of Doosan Infracore, nurturing the construction equipment business into another key growth pillar for the group. As Executive Vice Chairman, he directly oversaw major strategic issues across the HD Hyundai Group. More recently, he has focused on securing the company’s future growth engines — including artificial intelligence (AI), digital innovation, and eco-friendly core technologies — while strengthening cooperation with the United States, which has renewed its commitment to revitalizing the shipbuilding industry, by engaging with key U.S. figures.

An HD Hyundai official stated, “This appointment reflects our determination to pioneer a new era under strong leadership amid an increasingly competitive and diversified global business environment,” adding “By maintaining our leadership in the shipbuilding industry, HD Hyundai will contribute to the success of the Korea–U.S. Shipbuilding Cooperation Project, as well as to the growth of the Korean economy and the advancement of national interests.”

HANGZHOU, China, Oct. 20, 2025 /PRNewswire/ — On October 18, the Third Liangzhu Forum was held in Hangzhou, Zhejiang Province, jointly hosted by China’s Ministry of Culture and Tourism, the National Cultural Heritage Administration, and the Zhejiang Provincial People’s Government.

The year 2025 marks the 40th anniversary of China’s accession to the Convention Concerning the Protection of the World Cultural and Natural Heritage and the 20th anniversary of the adoption of UNESCO’s Convention on the Protection and Promotion of the Diversity of Cultural Expressions. Themed “Revitalization of Civilization: Cultural Heritage and Human Culture Diversity,” this year’s Liangzhu Forum brought together more than 300 participants from over 60 countries and regions, including senior officials from cultural heritage institutions, directors of museums, and leading archaeologists and historians. Participants engaged in substantive exchanges on topics including “Cultural Roots: Timeless Wisdom and Contemporary Value of Ancient Civilizations,” “Innovation in Practice: Urban Archaeology, Heritage Site Conservation and Coordinated Urban-Rural Development,” “Sustained Legacy: Expansion of Museum Functions and Utilization of Cultural Relics,” and “Future Vision: World Cultural Heritage and A New Model for Human Advancement.” The discussions highlighted shared commitments to safeguarding cultural heritage and promoting intercultural dialogue.

In conjunction with the forum, a series of cultural events were also held, including the Liangzhu Cultural and Creative Bazaar and the “Light of Liangzhu” symphony concert, a joint performance by Chinese and American orchestras.